QOL Assessment in BTCs: A Systematic Review of Phase 2 and 3 Clinical Trials

September 2022, Vol 3, No 3 — September 28, 2022

Although the clinical relevance of quality of life (QOL) is increasingly being acknowledged, it is rarely included as a clinical study end point in biliary tract cancers (BTCs). A systematic review was conducted to characterize the assessment and reporting of QOL in phase 2 and 3 clinical trials conducted in patients with BTC.

A literature search was performed of primary publications of phase 2 and 3 clinical trials evaluating anticancer drugs in patients with BTC published between 2010 and 2021 by 7 relevant scientific journals. The authors extracted data concerning QOL from primary, secondary, or exploratory end points; presence of QOL results; and methodology of QOL analyses from papers and study protocols.

A total of 49 publications were identified. Of these, 2 were in the adjuvant setting, 27 in first-line, 3 in first-line and beyond, 8 in second-line, and 9 in second-line and beyond. All studies included intrahepatic and extrahepatic cancers; 41/42 included gallbladder cancers, and ampullar neoplasms were rarely included (6/42).

The majority of publications (71.4%) did not list QOL among the end points. This trend was consistent over time (ie, between 2010 and 2015 and between 2016 and 2021). Trials conducted in Western populations were more likely to include QOL as a primary end point. In the metastatic setting, QOL was a secondary end point in 21.3% of trials and an exploratory end point in 4.3% of trials. Of the 14 primary publications of trials reporting QOL as a primary, secondary, or exploratory end point, QOL results were published in less than half of the papers (42.8%). The most common QOL tools used were EORTC QLQ-C30 (European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire; 57.1%) and EuroQoL-5D (European Quality of Life Five Dimension, and EuroQol five-dimensional; 21.4%).

Findings of this systematic review indicate that phase 2 and 3 clinical trials conducted in the past decade did not routinely include QOL assessments as a trial outcome. The authors noted that this was true “even in metastatic setting where QOL data should be fundamental for the optimal management of patients.”

Source: Tober N, Fillipini DM, Pagani R, et al. Quality of life assessment in biliary tract cancer: a systematic review of phase 2 and 3 clinical trials published between 2010 and 2021. Abstract P-144.

Related Items

Phase 3 Trial of Infigratinib vs GemCis in Patients with Advanced CCA with an FGFR2 Gene Fusion/Rearrangement: PROOF 301
September 2022, Vol 3, No 3
First-line treatment options are limited to gemcitabine/cisplatin (GemCis) for patients with advanced cholangiocarcinoma (CCA).
Pemigatinib for Metastatic CCA: Final Results from FIGHT-202
September 2022, Vol 3, No 3
Pemigatinib is an oral, potent, selective fibroblast growth factor receptor (FGFR)1-3 inhibitor that is currently approved for the treatment of adults with previously treated, unresectable, locally advanced/metastatic cholangiocarcinoma (CCA) bearing an FGFR2 fusion or other rearrangement based on the FIGHT-202 trial.
Outcomes by Primary Tumor Location in Patients with Advanced BTCs: Subanalysis of Phase 3 TOPAZ-1
September 2022, Vol 3, No 3
Results of the randomized, double-blind, global, phase 3 TOPAZ-1 trial (NCT03875235) demonstrated that the first-line chemoimmunotherapy regimen of the PD-L1 inhibitor durvalumab plus gemcitabine/cisplatin (GemCis; median follow-up, 13.7 months) significantly improved overall survival (OS) versus placebo plus GemCis (median follow-up, 12.6 months).1
Outcomes by Disease Status in Patients with Advanced BTCs: Subanalysis of Phase 3 TOPAZ-1
September 2022, Vol 3, No 3
Results of the randomized, double-blind, global, phase 3 TOPAZ-1 trial (NCT03875235) demonstrated that the first-line chemoimmunotherapy regimen of the PD-L1 inhibitor durvalumab plus gemcitabine/cisplatin (GemCis; median follow-up, 13.7 months) significantly improved overall survival (OS) versus placebo plus GemCis (median follow-up, 12.6 months).1
Tumor Markers in Patients with Advanced BTCs Treated with Second-Line ASC Alone or with FOLFOX: The ABC-06 Trial
September 2022, Vol 3, No 3
The randomized, open-label, multicenter, phase 3 ABC-06 trial established folinic acid/fluorouracil/oxaliplatin chemotherapy (FOLFOX) plus active symptom control (ASC) as the standard-of-care second-line treatment in patients with advanced biliary tract cancers (BTCs).1
CCA Summit Live from ESMO GI 2022
By Angela Lamarca, MD, PhD, MSc
Videos
Angela Lamarca, MD, PhD, MSc, Consultant (FEA) in Medical Oncology presents an overview of key abstracts on cholangiocarcinoma (CCA) presented at the 2022 annual meeting of the ESMO World Congress on Gastrointestinal Cancer (ESMO GI 2022).

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: